학술논문
Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
Document Type
Article
Author
Source
Subject
*PATIENTS
*PATIENT-professional relations
*THERAPEUTICS
*DOSAGE forms of drugs
*EVALUATION of medical care
*
*
*
*
Language
ISSN
1464-2662
Abstract
Background Patients prefer fewer pills and once-daily (qd) dosing without food restrictions. We assessed the impact on adherence [by Medication Event Monitoring System (MEMS) cap monitoring] of switching from abacavir (ABC) and lamivudine (3TC) twice daily (bid) to ABC/3TC fixed-dose formulation (FDC, Kivexa®) qd to achieve a qd regimen. Methods A randomized, open-label, 8-week study comparing adherence, efficacy and safety of immediate vs. delayed switching from ABC/3TC to FDC qd. Results Ninety-four patients were dosed. Significantly improved adherence was observed at week 4 with qd ABC/3TC across all three adherence variables: taking compliance 99.2% (90.7–100%) vs. 96.6% (60.0–100%) ( P=0.017); dosing compliance 97.1% (64.3–100%) vs. 91.9% (33.3–100%) ( P=0.016); and timing compliance 95.5% (53.8–100%) vs. 86.3% (4.3–100%) ( P=0.006). Treatment satisfaction increased significantly at week 4 with ABC/3TC qd [92% (82–99%) vs. 85% (75–93%) ( P=0.004)]. Two patients were withdrawn from the study because of intolerance to ABC/3TC. Conclusions Switching from ABC and 3TC bid to ABC/3TC FDC qd significantly improved adherence by MEMS cap monitoring at week 4 and improved patient satisfaction with therapy. The results remain to be confirmed over a longer follow-up. Use of qd regimens supports adherence and improves treatment satisfaction relative to bid regimens. [ABSTRACT FROM AUTHOR]